Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7439294 | 0.98 | OXTR (0.38) | OXTRHSD11B1MCHR2 | |
| SCHEMBL240993 | 0.82 | OXTR (0.46) | OXTRHSD11B1MCHR2 | |
| SCHEMBL15717910 | 0.76 | OXTR (0.51) | OXTRHSD11B1MCHR2 | |
| SCHEMBL241800 | 0.74 | OXTR (0.41) | OXTRHSD11B1MCHR2 | |
| SCHEMBL3923960 | 0.72 | OXTR (0.49) | OXTRHSD11B1 | |
| SCHEMBL11122795 | 0.72 | OXTR (0.49) | OXTRHSD11B1 | |
| SCHEMBL24505981 | 0.71 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL1115211 | 0.68 | OXTR (0.46) | OXTRHSD11B1MCHR2 | |
| SCHEMBL762110 | 0.68 | HTR2C (0.49) | OXTRHSD11B1MCHR2 | |
| SCHEMBL29790904 | 0.68 | OXTR (0.46) | OXTRHSD11B1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-5756504-A | TREATMENT OF DYSMENORRHEA, PREVENTION OF PREMATURE LABOR | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0751773-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0751773-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| US-5464788-A | Stopping labor | MERCK & CO., INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995025443-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | OXTR 780/4885HSD11B1 1187/4885MCHR2 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.